Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
You may also like
NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]
New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies […]
New York City, New York Feb 23, 2021 (Issuewire.com) – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies […]